Alembic Pharmaceuticals is currently trading at Rs. 532.05, up by 2.50 points or 0.47% from its previous closing of Rs. 529.55 on the BSE.
The scrip opened at Rs. 537.00 and has touched a high and low of Rs. 537.00 and Rs. 532.05 respectively. So far 446 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 542.35 and Rs. 527.10 respectively. The current market cap of the company is Rs. 10103.51 crore.
The promoters holding in the company stood at 72.96%, while Institutions and Non-Institutions held 15.05% and 11.99% respectively.
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tadalafil Tablets USP, 2.5 mg, 5 mg, 10-mg and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg, of Eli Lilly and Company (Lilly). All strengths of Tadalafil Tablets are indicated for the treatment of erectile dysfunction (ED).
Tadalafil Tablet 5mg strength is additionally indicated for treatment of signs and symptoms of benign prostatic hyperplasia (BPH). Alembic had previously received tentative approval for this ANDA. Tadalafil Tablets have an estimated market size of $1.8 billion for twelve months ending December 2018 according to IQVIA.
Alembic now has a total of 89 ANDA approvals (77 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1817.60 |
Dr. Reddys Lab | 1351.25 |
Cipla | 1475.90 |
Lupin | 2168.30 |
Zydus Lifesciences | 964.40 |
View more.. |